Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2017-11-28 Interim / Quarterly Rep…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Third quarter 2017 report and presentation
Interim / Quarterly Report Classification · 100% confidence The document is a 'Third Quarter Report' for 2017, which contains substantive financial data (income statement, cash flow, operating results) and detailed management analysis of clinical programs (fimaCHEM, fimaVACC, fimaNAC). It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2017
2017-11-28 English
PCI Biotech: Third quarter 2017 report and presentation
Investor Presentation Classification · 98% confidence The document is titled 'Q3 2017 PRESENTATION' and contains financial highlights for Q3 2017, including operating results and cash equivalents for Q3 and Year-to-Date (YTD). It details clinical trial progress for drug candidates (fimaCHEM, fimaVACC, fimaNAC) and outlines anticipated key milestones through 2018. This structure—a presentation summarizing quarterly performance, pipeline updates, and financial data—is characteristic of an Investor Presentation (IP) or a presentation accompanying an Earnings Release (ER). Since it is explicitly labeled as a 'PRESENTATION' and provides detailed operational and financial summaries rather than just the initial press release highlights, 'Investor Presentation' (IP) is the most accurate classification. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather a presentation summarizing the period.
2017-11-28 English
PCI Biotech: Third quarter 2017 report and presentation
Report Publication Announcement Classification · 95% confidence The document is a short announcement (approx. 5,600 characters) from PCI Biotech regarding the release of their third-quarter 2017 report and presentation. It explicitly states 'Please find enclosed the financial report and presentation', which indicates that the document itself is an announcement of the report's availability rather than the full financial report itself. According to the 'Menu vs Meal' rule, this qualifies as a Report Publication Announcement (RPA). Q3 2017
2017-11-28 English
PCI Biotech: Invitation to third quarter 2017 presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation to a presentation covering the company's 'third quarter 2017 report'. It explicitly states that the 'interim report and the presentation will be available' at a specific time and location. Since the document itself is an announcement about the release and presentation of a periodic financial report (Q3), and not the full report or the transcript of the call, it fits the definition of a Report Publication Announcement (RPA). The document length (1303 chars) is very short, supporting the RPA classification over the full Interim Report (IR) or Call Transcript (CT).
2017-11-21 English
PCI Biotech: Board of Directors update
Board/Management Information Classification · 100% confidence The document explicitly announces an update regarding the Board of Directors of PCI Biotech Holding ASA, stating that a current director, Prof. Kjetil Taskén, will not seek re-election due to a new appointment. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is short, but the content is the announcement itself, not a notice about an attached report.
2017-11-09 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, including 'Quarterly Report - Q3', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, nor is it an announcement of a specific report release that has just occurred. It is a forward-looking schedule of key financial and corporate events. This type of general schedule announcement does not fit precisely into the defined categories (like ER, IR, 10-K, AGM-R). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general corporate disclosure.
2017-11-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.